Citadel Advisors
TRVI icon

Citadel Advisors’s Trevi Therapeutics TRVI Stock Holding History

Citadel Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,201,489
Closed -$17.5M – 14868
2026
Q1 		$14.3M Buy
1,201,489
+1,048,634
+686% +$11.7M ﹤0.01% 2745
2025
Q4 		$1.91M Buy
152,855
+50,321
+49% +$582K ﹤0.01% 6006
2025
Q3 		$938K Sell
102,534
-1,216,732
-92% -$9.12M ﹤0.01% 7666
2025
Q2 		$7.22M Buy
+1,319,266
New +$8.21M ﹤0.01% 3507
2025
Q1 		– Sell
-1,233,176
Closed -$5.88M – 15586
2024
Q4 		$5.08M Buy
1,233,176
+1,183,295
+2,372% +$3.79M ﹤0.01% 3939
2024
Q3 		$167K Buy
+49,881
New +$148K ﹤0.01% 10423
2024
Q2 		– Sell
-28,680
Closed -$98.9K – 15428
2024
Q1 		$98.9K Sell
28,680
-156,378
-85% -$349K ﹤0.01% 11372
2023
Q4 		$248K Buy
185,058
+157,977
+583% +$239K ﹤0.01% 9539
2023
Q3 		$59K Sell
27,081
-33,372
-55% -$75.4K ﹤0.01% 11558
2023
Q2 		$144K Sell
60,453
-11,202
-16% -$28.2K ﹤0.01% 10396
2023
Q1 		$133K Buy
71,655
+27,439
+62% +$62.1K ﹤0.01% 10836
2022
Q4 		$85.3K Buy
+44,216
New +$87.2K ﹤0.01% 11437
2022
Q1 		– Sell
-49,849
Closed -$39K – 14594
2021
Q4 		$39K Buy
49,849
+31,702
+175% +$33.3K ﹤0.01% 13382
2021
Q3 		$25K Buy
+18,147
New +$32.1K ﹤0.01% 13615
2021
Q2 		– Sell
-10,617
Closed -$29K – 14453
2021
Q1 		$29K Buy
+10,617
New +$31.1K ﹤0.01% 13037

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Citadel Advisors's TRVI Position: Q2 2026 in Review

Citadel Advisors sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 1,201,489 shares — an estimated $17.5M sold.

Citadel Advisors first reported a position in TRVI in Q1 2021 and held it in 15 quarters. The position peaked at $14.3M in Q1 2026. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Citadel Advisors reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,201,489 Trevi Therapeutics shares in Q2 2026, an estimated $17.5M.
  • Citadel Advisors first reported a position in Trevi Therapeutics in Q1 2021 and held it in 15 quarters.
  • Citadel Advisors's Trevi Therapeutics position peaked at $14.3M in Q1 2026.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.